Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S‑[(1‑Hydroxy‑2,2,5,5‑tetramethyl‑4‑phenyl‑2,5‑dihydro‑1H-pyrrol‑3‑yl)methyl] methanesulfonothioate is a synthetic small molecule with the chemical formula C16H23NO3S2 and a molecular weight of approximately 341.49 g/mol[1][2]. It is classified as an experimental compound and has not been approved for any medical use in the US or other major regulatory jurisdictions[1][3]. There are no known clinical trials or indications associated with this molecule. Its mechanism of action and pharmacological properties have not been described in publicly available sources. The compound belongs to the class of pyrroline derivatives but does not have established therapeutic applications or known biological targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-[(1-hydroxy-2,2,5,5-tetramethyl-4-phenyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate.